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OBJECTIVE — To determine whether, in accordance with observations in mouse models,
highconcentrationsofthelipoproteinlipaseinhibitorsapolipoprotein(Apo)CIandApoCIIIare
associated with increased triglyceride concentrations and decreased fat mass in men with the
metabolic syndrome.
RESEARCH DESIGN AND METHODS — Plasma ApoCI, ApoCIII, and triglyceride
concentrations were measured in the postabsorptive state in 98 men with the metabolic syn-
drome. Subcutaneous and visceral fat areas were measured by 3T-magnetic resonance imaging.
RESULTS — Triglyceride concentrations were 49% higher, and the average visceral fat area
was 26% lower (both P  0.001), in subjects with high ApoCI and ApoCIII compared with low
ApoCI and ApoCIII. Subjects with either high ApoCI or ApoCIII had 16% (P  0.05) and 18%
(P  0.01) decreased visceral fat area, respectively.
CONCLUSIONS — High concentrations of ApoCI and ApoCIII are associated with in-
creasedtriglyceridesanddecreasedvisceralfatmassinmenwiththemetabolicsyndrome.These
ﬁndings translate mouse studies into human pathophysiology.
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A
polipoprotein (Apo) CI and Apo-
CIII are present on HDL and tri-
glyceride(TG)-richlipoproteins(1)
and mainly affect plasma lipid metabo-
lism by inhibition of lipoprotein lipase
(LPL) (2). This enzyme hydrolyzes TG in
VLDL and chylomicrons, releasing fatty
acids for storage by adipocytes or for en-
ergy metabolism in muscles (2,3). Over-
expression of human ApoCI in mice
increases VLDL-associated TG plasma
levels in combination with decreased
body fat (4). The effect of ApoCIII over-
expression is unknown, but ApoCIII de-
ﬁciency in mice led to lower VLDL-
associated TG levels and increased diet-
induced obesity (5). Because it has
recently been shown that LPL activity is
higher in visceral adipose tissue (VAT)
compared with subcutaneous adipose tis-
sue (SAT) (6), LPL inhibitors such as
ApoCI and ApoCIII may differentially af-
fect VAT compared with SAT. The objec-
tive of this study was to determine
whether, like in mouse models, high
ApoCI and ApoCIII concentrations are
associated with increased TG concen-
trations and decreased fat mass (VAT
vs. SAT) in men with the metabolic
syndrome.
RESEARCH DESIGN AND
METHODS— We studied 98 male
subjects aged 50–70 years with the met-
abolic syndrome (deﬁned using Interna-
tional Diabetes Federation criteria [7]).
Exclusion criteria were the presence of
type 2 diabetes, overt cardiovascular dis-
ease, use of statins or ﬁbrates, and a BMI
40 kg/m
2. The study protocol was ap-
proved by the local ethics committee.
Blood samples were collected after a 12-h
overnight fast. Plasma concentrations of
ApoCI and ApoCIII were determined us-
ing sandwich enzyme-linked immu-
nosorbent assays speciﬁc for human
ApoCI and ApoCIII (8).
Magnetic resonance imaging (MRI),
measuring SAT and VAT area at the level
of the intervertebral disk level between
the fourth and ﬁfth lumbar vertebra, was
performed on a 3T scanner (Philips;
Achieva, Best, the Netherlands) as de-
scribed previously (9).
Toaddressthequestionwhetherhigh
ApoCI, high ApoCIII, and the combina-
tion of high ApoCI and ApoCIII are asso-
ciated with increased TG concentrations
and decreased VAT and SAT area, the
study subjects were divided into groups
according to median ApoCI concentra-
tion (6.38 mg/dl; skewed distribution)
and mean ApoCIII concentration (10.2
mg/dl; normal distribution).
Statistical analyses were performed
using SPSS version 14.0 for Windows.
The level of signiﬁcance was set at 0.05.
Differences in clinical and laboratory pa-
rameters and SAT and VAT area were as-
sessed by independent t test or one-way
ANOVA, with post hoc least signiﬁcant
difference testing, if appropriate. Mann-
Whitney tests or Kruskall-Wallis tests
(followed by Mann-Whitney tests, P val-
uesweremultipliedbythreetocorrectfor
multiple testing) were performed for pa-
rameters that were not normally distrib-
uted. Smoking frequency was assessed by
Pearson 
2 tests. Correlations were calcu-
lated using Spearman’s .
RESULTS— Clinical and laboratory
parameters, including waist circumfer-
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ment, were not different between the
four groups, apart from HDL choles-
terol, total cholesterol, and smoking
(see Table A1a in the online appendix
available at http://dx.doi.org/10.2337/
dc08-1330). There were more smokers
in the group with high ApoCIII com-
pared with low ApoCIII (33 and 7%,
respectively; P  0.01).
ApoCI and ApoCIII levels were posi-
tively correlated (0.405, P  0.001).
TG concentrations were 49% higher in
subjects with both high ApoCI and
ApoCIII compared with subjects with
low ApoCI and ApoCIII (P  0.001)
(Fig. 1A). Subjects with both high
ApoCI and ApoCIII had 26% decreased
VAT area (P  0.001) and 7% lower
SAT area (not signiﬁcant) compared
with subjects with both low ApoCI and
ApoCIII levels (Fig. 1B). Subjects with
ApoCIabovethemedianhad16%lower
VATarea(P  0.05)and3%higherSAT
area (not signiﬁcant). Subjects with
ApoCIII above the median had 18%
lower VAT area (P  0.01) and 14%
lower SAT area (not signiﬁcant).
To exclude the difference in smoking
frequency as a possible confounder, the
analysis was repeated after exclusion of
smokers. TG levels were slightly lower,
but for both TG and VAT area, the results
remained highly signiﬁcant (online ap-
pendix Table A1b).
CONCLUSIONS — High ApoCI and
ApoCIII concentrations are associated
withincreasedTGconcentrationsandde-
creased VAT area in men with the meta-
bolic syndrome. The phenotypic
appearances caused by modulation of
ApoCI and ApoCIII may be very relevant
for human subjects with the metabolic
syndrome, since visceral obesity and in-
creasedTGlevelsaretwoofitsmainchar-
acteristics (7). In addition, intra-
abdominal fat is presumed to be an
important determinant of metabolic dys-
regulation (10,11). The data presented in
this study are in line with experimental
data and indicate that the mechanisms
uncovered by these experimental studies
can be translated to the human situation.
To be more precise, these data suggest
that the known inhibition of LPL by
ApoCI and ApoCIII contributes to higher
TG and lower VAT area in human sub-
jects.Furthermore,thedifferenceineffect
of ApoCI and ApoCIII on TG concentra-
tions observed in this study underlines
the stronger inhibition of LPL by ApoCIII
compared with ApoCI, as shown in ex-
perimental studies (2).
ApoCI and ApoCIII levels were
mainly related to the VAT compartment.
This can be related to a higher expression
ofLPLinVATversusSAT,asevidentfrom
experimental studies in mice (6). Alterna-
tively,LPLmaybedifferentlyregulatedin
various fat depositions (e.g., VAT vs.
SAT). This adds to the discussion relating
LPL to fat deposition, since studies com-
paring LPL mass, activity, and mRNA ex-
pression between subcutaneous and
visceral fat have shown contradictory re-
sults (10,12,13). The difference in smok-
ing frequency has not confounded our
results, because when the analysis was re-
peated after exclusion of smokers, almost
identical results were obtained.
The current observations are re-
stricted to male, abdominally obese sub-
jects, aged 50–70 years, without type 2
diabetesorcardiovasculardisease.Never-
theless, this study shows that in men with
Figure 1—Illustration of the inverse relationship of ApoCI and ApoCIII concentrations with
plasmatriglycerideconcentration(positive,A)andwithvisceraladiposetissuearea(negative,B).
ApoCI/ApoCIII  median/mean  low, ApoCI/ApoCIII  median/mean  high. Groups: 1: low
ApoCI and ApoCIII (n  35); 2: high ApoCI/low ApoCIII (n  21); 3: low ApoCI/high ApoCIII
(n  14); 4: high ApoCI and ApoCIII (n  28). Triglyceride concentration: 1 vs. 3, 1 vs. 4, and 2
vs. 4: P  0.001. 2 vs. 3: P  0.01. Visceral adipose tissue area: low ApoCI and ApoCIII vs. high
ApoCI and ApoCIII: P  0.001.
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ApoCIII levels are associated with in-
creased TG levels and decreased visceral
fat mass, which is in line with in vivo data
frommousemodels.Thisstudyistheﬁrst
to address the effect of LPL regulation on
adipose tissue deposition in humans and
necessitatesfurtherstudiesontheeffectof
LPL, the LPL coactivator ApoCII, and
their polymorphisms on adipose tissue
mass.
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